恆瑞醫藥(600276.SH)獲鹽酸普拉克索緩釋片藥品註冊證書
格隆匯10月22日丨恆瑞醫藥(600276.SH)公佈,公司近日收到國家藥品監督管理局核准簽發關於鹽酸普拉克索緩釋片的《藥品註冊證書》。
2017年10月19日,恆瑞醫藥向江蘇省食品藥品監督管理局遞交的藥品註冊申請獲得受理。鹽酸普拉克索緩釋片是一種多巴胺受體激動劑,通過興奮紋狀體的多巴胺受體減輕帕金森病患者的運動障礙,用於治療成人特發性帕金森病的體徵和症狀。截至目前,該產品累計已投入研發費用約為1832萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.